Related Experiment Videos
Phase II study of medroxyprogesterone acetate with tamoxifen in advanced renal cell cancer
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2003
Pleurx tunneled catheter in the management of malignant ascites.
Journal of vascular and interventional radiology : JVIR·2001
Phase I study of docetaxel and topotecan in patients with solid tumors.
Cancer chemotherapy and pharmacology·2001
Cisplatin as a first-line treatment in T2 and T3 bladder carcinoma.
Cancer treatment reports·1987
IV melphalan in children.
Cancer treatment reports·1987
Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.
Cancer treatment reports·1987
Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.
Cancer treatment reports·1987
Doxorubicin distribution in human breast cancer.
Cancer treatment reports·1987
Phase I study of echinomycin.
Cancer treatment reports·1987
Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".
Current oncology (Toronto, Ont.)·2026
Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.
Current oncology (Toronto, Ont.)·2026
[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.
Current oncology (Toronto, Ont.)·2026
A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.
Current oncology (Toronto, Ont.)·2026